As the recipient of a $3 million, 3-year Phase II SBIR grant, ID Genomics has been selected for the Commercialization Acceleration Program sponsored by the National Institutes of Health and the Larta Institute. The goal of this program is to assist early stage companies in commercializing their technology by expanding their network to include experts in industry, finance, and regulation. IDG was selected as one of seventy six (76) companies from submissions across the US.
https://portal.larta.org/nih/home
